Anti-interleukin-18 receptor nanobody and use thereof
By developing nano-antibody targeting IL-18R1, blocking the IL-18/IL-18R pathway, the problem of inability to effectively block IL-18R1 in the prior art has been solved, effective treatment of related diseases has been achieved, and new treatment ideas.
Patent Information
- Application Number
- PCT/CN2023/097235
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
The existing IL-18 inhibitors do not have nano-antibody targeting interleukin 18 receptor 1 (IL-18R1), and cannot effectively block the IL-18/IL-18R pathway, limiting the therapeutic effect on related diseases.
A nanoantibody targeting IL-18R1 was developed to block the interaction between IL-18 and IL-18R1 by specifically binding IL-18R1, and has a blocking activity better than the interleukin-18 binding protein (IL-18BP). , used to treat diseases related to the IL-18/IL-18R pathway.
This nanoantibodies can effectively recognize and bind IL-18R1 in humans and cynomolgus monkeys, have good blocking activity, are better than the existing IL-18BP, and provide new treatment ideas, for rheumatoid arthritis, systemic lupus erythematosus, etc. Disease has potential therapeutic effects.
Smart Images

Figure PCTCN2023097235-FTAPPB-I100001 
Figure PCTCN2023097235-FTAPPB-I100002 
Figure PCTCN2023097235-FTAPPB-I100003
Abstract
Description
Anti-interleukin-18 receptor nanoantibodies and their applications Technical Field
[0001] The present invention relates to the field of antibody drugs, and in particular to a nanobody targeting interleukin-18 receptor and applications thereof. Background Art
[0002] Interleukin-18 (IL-18) is a potent proinflammatory cytokine produced by multiple cell types, including hematopoietic and non-hematopoietic cells. It participates in host defense against infection and regulates innate and adaptive immune responses. IL-18 can regulate both innate and adaptive immunity, and its dysregulation may lead to autoimmune or inflammatory diseases. Clinical reports have shown that elevated IL-18 levels in the blood of patients with some immune-related diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, type 1 diabetes, atopic dermatitis, psoriasis, and inflammatory bowel disease, are positively correlated with IL-18 levels. Clinical studies have shown that inhibiting the IL-18 signaling pathway can effectively treat rare diseases such as hemophagocytic lymphohistiocytosis (HLH) and adult-onset Still's disease, and may also have a positive effect on chronic pulmonary sarcoidosis.
[0003] The IL-18 receptor consists of an inducible component, interleukin-18 receptor 1 (IL-18R1), which binds mature IL-18 with low affinity and a constitutively expressed co-receptor, interleukin-18 receptor 2 (IL-18R2). IL-18 binds to the ligand receptor IL-18R1, inducing the recruitment of IL-18R2 to form a high-affinity complex that signals through the toll / interleukin-1 receptor (TIR) domain. This signaling domain activates the MyD88 adaptor protein, a proinflammatory cascade and the NF-κB pathway. IL-18 activity can be inhibited by the bound extracellular interleukin-18 binding protein (IL-18BP). Soluble IL-18 binds with higher affinity than IL-18R1, thereby preventing IL-18 from binding to the IL-18 receptor. Clinical studies have shown that using IL-18BP to block the signaling pathway caused by IL-18 has shown good therapeutic effects in hemophagocytic lymphohistiocytosis and adult-onset Still's disease; at the same time, the drug has shown good tolerability and safety, achieving the primary endpoint of the Phase II clinical study.
[0004] Existing IL-18 inhibitors include IL-18R1 monoclonal antibodies and IL-18BP, but no nanobodies targeting this target have been reported. Therefore, research to obtain novel therapeutic IL-18 / IL-18R1 blocking nanobodies is of certain significance and may provide new clinical treatment ideas.
[0005] Summary of the Invention
[0006] The object of the present invention is to provide a nanobody targeting interleukin-18 receptor 1, and the use of the nanobody in detection and disease treatment.
[0007] In a first aspect of the present invention, an anti-IL-18R1 Nanobody is provided, wherein the Nanobody is capable of specifically binding to IL-18R1, and the complementarity determining region (CDR) of the VHH chain in the Nanobody is one or more selected from the following groups:
[0008] (1) CDR1 shown in SEQ ID NO: 12, CDR2 shown in SEQ ID NO: 13, and CDR3 shown in SEQ ID NO: 14; and
[0009] (2) CDR1 shown in SEQ ID NO: 9, CDR2 shown in SEQ ID NO: 10, and CDR3 shown in SEQ ID NO: 11.
[0010] In another preferred example, the VHH chain of the anti-IL-18R1 nanobody further comprises a framework region (FR), and the framework region (FR) comprises human FR and camel FR.
[0011] In another preferred embodiment, the framework region (FR) is one or more selected from the following groups:
[0012] (1) FR1 shown in SEQ ID NO: 25, FR2 shown in SEQ ID NO: 20, FR3 shown in SEQ ID NO: 21, and FR4 shown in SEQ ID NO: 26;
[0013] (2) FR1 shown in SEQ ID NO: 19, FR2 shown in SEQ ID NO: 20, FR3 shown in SEQ ID NO: 21, and FR4 shown in SEQ ID NO: 22;
[0014] (3) FR1 shown in SEQ ID NO: 23, FR2 shown in SEQ ID NO: 16, FR3 shown in SEQ ID NO: 17, and FR4 shown in SEQ ID NO: 24; and
[0015] (4) FR1 shown in SEQ ID NO: 15, FR2 shown in SEQ ID NO: 16, FR3 shown in SEQ ID NO: 17, and FR4 shown in SEQ ID NO: 18.
[0016] In another preferred example, the amino acid sequence of the VHH chain of the anti-IL-18R1 Nanobody is selected from the following group: SEQ ID NO: 4, SEQ ID NO: 3, SEQ ID NO: 2, SEQ ID NO: 1, or a combination thereof.
[0017] In another preferred example, the VHH chain of the anti-IL-18R1 Nanobody has an amino acid sequence that is at least 75%, preferably at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in any one of SEQ ID NO: 4, SEQ ID NO: 3, SEQ ID NO: 2 or SEQ ID NO: 1.
[0018] In another preferred embodiment, the anti-IL-18R1 nanobody includes monomers, bivalents (bivalent antibodies), tetravalents (tetravalent antibodies), and / or multivalents (multivalent antibodies).
[0019] In another preferred embodiment, the anti-IL-18R1 nanobody includes humanized antibodies, camel-derived antibodies, and chimeric antibodies.
[0020] In another preferred embodiment, the anti-IL-18R1 Nanobody can recognize and bind to human and cynomolgus monkey IL-18R1.
[0021] In another preferred embodiment, the anti-IL-18R1 nanobody can effectively block the interaction between IL-18 and IL-18R1.
[0022] In another preferred embodiment, the anti-IL-18R1 nanobody has good blocking activity on the IL-18 / IL-18R pathway, which is better than the blocking activity of interleukin 18 binding protein (IL-18BP) on the IL-18 / IL-18R pathway.
[0023] The second aspect of the present invention provides an anti-IL-18R1 antibody, which comprises the VHH chain of the anti-IL-18R1 nanobody according to the first aspect of the present invention.
[0024] In another preferred embodiment, the anti-IL-18R1 antibody comprises one or more VHH chains having an amino acid sequence as shown in SEQ ID NO: 4, SEQ ID NO: 3, SEQ ID NO: 2 or SEQ ID NO: 1.
[0025] In another preferred embodiment, the anti-IL-18R1 antibody includes a monomer, a bivalent body (bivalent antibody), a tetravalent body (tetravalent antibody), and / or a multivalent body (multivalent antibody).
[0026] In a third aspect, the present invention provides an anti-IL-18R1 nanobody Fc fusion protein, wherein the structure of the fusion protein from N-terminus to C-terminus is as shown in Formula Ia or Ib:
[0027] ALB(Ia);
[0028] BLA(Ib);
[0029] in,
[0030] “-” is a peptide bond;
[0031] A is one or more anti-IL-18R1 Nanobodies as described in the first aspect of the present invention;
[0032] B is the Fc fragment of IgG; and
[0033] L is no or flexible joint.
[0034] In another preferred embodiment, the flexible linker is a connecting peptide.
[0035] In another preferred embodiment, the IgG Fc fragment includes the human IgG Fc fragment.
[0036] In another preferred embodiment, the IgG Fc fragment is selected from the following group: IgG1, IgG2, IgG3, IgG4 Fc fragment, or a combination thereof.
[0037] In another preferred embodiment, the connecting peptide is selected from the following sequences: (G a S b ) x —(G m S n ) y , where a, b, m, n, x, y = 0 or 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (preferably, a = 4 and b = 1, m = 3 and n = 1).
[0038] The fourth aspect of the present invention provides a polynucleotide encoding a protein selected from the following group: the anti-IL-18R1 nanobody as described in the first aspect of the present invention, the anti-IL-18R1 antibody as described in the second aspect of the present invention, or the anti-IL-18R1 nanobody Fc fusion protein as described in the third aspect of the present invention.
[0039] In another preferred embodiment, the polynucleotide includes DNA or RNA.
[0040] In another preferred embodiment, the polynucleotide comprises a sequence selected from the group consisting of a nucleotide sequence as shown in SEQ ID NO: 8, SEQ ID NO: 7, SEQ ID NO: 6 or SEQ ID NO: 5.
[0041] The fifth aspect of the present invention provides an expression vector, wherein the expression vector contains the polynucleotide as described in the fourth aspect of the present invention.
[0042] In another preferred embodiment, the expression vector is selected from the following group: DNA, RNA, viral vector, plasmid, transposon, other gene transfer systems, or a combination thereof.
[0043] Preferably, the expression vector comprises a viral vector, such as a lentivirus, adenovirus, AAV virus, retrovirus, or a combination thereof.
[0044] The sixth aspect of the present invention provides a host cell, which contains the expression vector described in the fifth aspect of the present invention, or the polynucleotide described in the fourth aspect of the present invention is integrated into its genome.
[0045] In another preferred embodiment, the host cell includes a prokaryotic cell or a eukaryotic cell.
[0046] In another preferred embodiment, the host cell is selected from the group consisting of Escherichia coli, yeast cells, mammalian cells, bacteriophages, or a combination thereof.
[0047] In another preferred embodiment, the prokaryotic cell is selected from the group consisting of Escherichia coli, Bacillus subtilis, lactic acid bacteria, Streptomyces, Proteus mirabilis, or a combination thereof.
[0048] In another preferred embodiment, the eukaryotic cell is selected from the group consisting of Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trichoderma, or a combination thereof.
[0049] In another preferred embodiment, the host cell is Pichia pastoris.
[0050] The seventh aspect of the present invention provides an immunoconjugate, comprising:
[0051] (a) the anti-IL-18R1 Nanobody as described in the first aspect of the invention, or the anti-IL-18R1 antibody as described in the second aspect of the invention, or the anti-IL-18R1 Nanobody Fc fusion protein as described in the third aspect of the invention; and
[0052] (b) a conjugated moiety selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, a gold nanoparticle / nanorod, a nanomagnetic particle, a viral coat protein or a VLP, or a combination thereof.
[0053] The eighth aspect of the present invention provides a pharmaceutical composition comprising:
[0054] (i) the anti-IL-18R1 Nanobody as described in the first aspect of the invention, or the anti-IL-18R1 antibody as described in the second aspect of the invention, or the anti-IL-18R1 Nanobody Fc fusion protein as described in the third aspect of the invention, or the immunoconjugate as described in the seventh aspect of the invention; and
[0055] (ii) a pharmaceutically acceptable carrier.
[0056] In another preferred embodiment, the pharmaceutical composition further contains other drugs for treating autoimmune diseases or inflammatory diseases.
[0057] In another preferred embodiment, the pharmaceutical composition is used to prepare a drug for preventing and / or treating diseases or conditions related to the IL-18 / IL-18R pathway.
[0058] In another preferred embodiment, the diseases or conditions include rheumatoid arthritis (RA), systemic lupus erythematosus, type 1 diabetes, atopic dermatitis, psoriasis, inflammatory bowel disease, as well as hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), adult Still's disease, systemic juvenile idiopathic arthritis (SJIA), etc.
[0059] A ninth aspect of the present invention provides a recombinant protein comprising:
[0060] (Z1) the anti-IL-18R1 Nanobody as described in the first aspect of the invention, or the anti-IL-18R1 antibody as described in the second aspect of the invention, or the anti-IL-18R1 Nanobody Fc fusion protein as described in the third aspect of the invention; and
[0061] (Z2) Optional tag sequence to facilitate expression and / or purification.
[0062] In another preferred embodiment, the tag sequence includes (but is not limited to) Flag tag, HA tag and 6His tag.
[0063] In the tenth aspect of the present invention, there is provided the use of the anti-IL-18R1 nanobody as described in the first aspect of the present invention, or the anti-IL-18R1 antibody as described in the second aspect of the present invention, or the anti-IL-18R1 nanobody Fc fusion protein as described in the third aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention, for: (a) preparing a drug for preventing and / or treating diseases or conditions related to the IL-18 / IL-18R pathway; (b) preparing a reagent, detection plate or kit for detecting IL-18R1.
[0064] In another preferred embodiment, the diseases or conditions include rheumatoid arthritis (RA), systemic lupus erythematosus, type 1 diabetes, atopic dermatitis, psoriasis, inflammatory bowel disease, as well as hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), adult Still's disease, systemic juvenile idiopathic arthritis (SJIA), etc.
[0065] In another preferred embodiment, the reagent is a diagnostic reagent.
[0066] In another preferred embodiment, the reagent is used to detect IL-18R1 protein in a sample.
[0067] In another preferred embodiment, the IL-18R1 includes human IL-18R1 and cynomolgus monkey IL-18R1.
[0068] In the eleventh aspect of the present invention, a multispecific antibody is provided, which comprises the anti-IL-18R1 nanobody as described in the first aspect of the present invention, or the anti-IL-18R1 antibody as described in the second aspect of the present invention.
[0069] In another preferred embodiment, the multispecific antibody further comprises a second antigen binding region targeting a target selected from the group consisting of IL-4R, IL-4Rα, IL-5, IL-5R, IL-13, IL-13R, IL-11, IL-11R, or a combination thereof.
[0070] In another preferred embodiment, the second antigen binding region is a nanobody.
[0071] In another preferred embodiment, the multispecific antibody comprises one or more second antigen binding regions.
[0072] In another preferred embodiment, the multispecific antibody further comprises an antibody Fc segment.
[0073] The twelfth aspect of the present invention provides the use of the anti-IL-18R1 nanobody as described in the first aspect of the present invention, or the anti-IL-18R1 antibody as described in the second aspect of the present invention, or the anti-IL-18R1 nanobody Fc fusion protein as described in the third aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention, for detecting IL-18R1 protein in a sample, or for treating and / or preventing diseases or conditions related to the IL-18 / IL-18R pathway.
[0074] In another preferred embodiment, the detection includes flow cytometry detection, ELISA detection, and cell immunofluorescence detection.
[0075] In another preferred embodiment, the diseases or conditions include rheumatoid arthritis (RA), systemic lupus erythematosus, type 1 diabetes, atopic dermatitis, psoriasis, inflammatory bowel disease, as well as hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), adult Still's disease, systemic juvenile idiopathic arthritis (SJIA), etc.
[0076] In another preferred embodiment, the use is diagnostic and / or non-diagnostic, and / or therapeutic and / or non-therapeutic.
[0077] The thirteenth aspect of the present invention provides a method for detecting IL-18R1 protein in a sample, the method comprising the steps of:
[0078] (1) contacting the sample with the anti-IL-18R1 nanobody as described in the first aspect of the present invention, or the anti-IL-18R1 antibody as described in the second aspect of the present invention, or the anti-IL-18R1 nanobody Fc fusion protein as described in the third aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention;
[0079] (2) Detecting whether an antigen-antibody complex is formed, wherein the formation of the complex indicates the presence of IL-18R1 protein in the sample.
[0080] In another preferred embodiment, the method is a non-diagnostic and non-therapeutic method.
[0081] A fourteenth aspect of the present invention provides an IL-18R1 protein detection reagent, comprising:
[0082] (C1) the anti-IL-18R1 Nanobody as described in the first aspect of the invention, or the anti-IL-18R1 antibody as described in the second aspect of the invention, or the anti-IL-18R1 Nanobody Fc fusion protein as described in the third aspect of the invention, or the immunoconjugate as described in the seventh aspect of the invention; and
[0083] (C2) A carrier that is acceptable for detection.
[0084] In another preferred embodiment, the conjugated portion of the immunoconjugate is a diagnostic isotope.
[0085] In another preferred embodiment, the assay-acceptable carrier is a non-toxic, inert aqueous carrier medium.
[0086] In another preferred embodiment, the detection reagent is one or more reagents selected from the following group: isotope tracers, contrast agents, flow cytometry detection reagents, cell immunofluorescence detection reagents, nanomagnetic particles and imaging agents.
[0087] In another preferred embodiment, the detection reagent is used for in vivo detection.
[0088] In another preferred embodiment, the dosage form of the detection reagent is liquid or powder (such as aqueous solution, injection, lyophilized powder, tablet, buccal preparation, inhaler).
[0089] In a fifteenth aspect, the present invention provides a kit for detecting IL-18R1 protein, wherein the kit comprises the detection reagent as described in the fourteenth aspect of the present invention, and instructions.
[0090] In another preferred embodiment, the instructions state that the kit is used for non-invasively detecting IL-18R1 expression in a subject.
[0091] In the sixteenth aspect of the present invention, an IL-18 inhibitor is provided, which comprises the anti-IL-18R1 nanobody as described in the first aspect of the present invention, or the anti-IL-18R1 antibody as described in the second aspect of the present invention, or the anti-IL-18R1 nanobody Fc fusion protein as described in the third aspect of the present invention.
[0092] In another preferred embodiment, the IL-18 inhibitor blocks the interaction between IL-18 and IL-18R1, thereby blocking the IL-18 / IL-18R pathway and inhibiting the functional activity of IL-18.
[0093] In the seventeenth aspect of the present invention, a method for preventing and / or treating diseases or conditions related to the IL-18 / IL-18R pathway is provided, comprising the steps of administering to a subject in need thereof the anti-IL-18R1 nanobody as described in the first aspect of the present invention, or the anti-IL-18R1 antibody as described in the second aspect of the present invention, or the anti-IL-18R1 nanobody Fc fusion protein as described in the third aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention, or the pharmaceutical composition as described in the eighth aspect of the present invention.
[0094] In another preferred embodiment, the diseases or conditions include rheumatoid arthritis (RA), systemic lupus erythematosus, type 1 diabetes, atopic dermatitis, psoriasis, inflammatory bowel disease, as well as hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), adult Still's disease, systemic juvenile idiopathic arthritis (SJIA), etc.
[0095] In another preferred embodiment, the subject in need thereof is a human or a non-human mammal (eg, cynomolgus monkey).
[0096] In the eighteenth aspect of the present invention, a chimeric antigen receptor (CAR) is provided, the antigen binding domain of which comprises the anti-IL-18R1 nanobody as described in the first aspect of the present invention, or the anti-IL-18R1 antibody as described in the second aspect of the present invention.
[0097] Furthermore, an engineered cell expressing the chimeric antigen receptor is provided.
[0098] In another preferred embodiment, the cells are immune cells, such as T cells and NK cells.
[0099] Furthermore, provided are uses of the engineered cells for preparing a medicament for preventing and / or treating a disease or condition associated with the IL-18 / IL-18R pathway; or a method for preventing and / or treating a disease or condition associated with the IL-18 / IL-18R pathway.
[0100] In another preferred embodiment, the diseases or conditions include rheumatoid arthritis (RA), systemic lupus erythematosus, type 1 diabetes, atopic dermatitis, psoriasis, inflammatory bowel disease, as well as hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), adult Still's disease, systemic juvenile idiopathic arthritis (SJIA), etc.
[0101] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0102] Figure 1 shows the inhibitory effect of candidate IL-18R1 nanobodies on reporter gene cell signaling pathways.
[0103] Figure 2 shows the binding activity of humanized Nanobody HuNb7 to IL-18R1 (ELISA).
[0104] Figure 3 shows the binding activity of humanized Nanobody HuNb24 to IL-18R1 (ELISA).
[0105] Figure 4 shows the binding activity of humanized nanobody HuNb7 to human IL-18R1 stably transfected cell lines (FACS).
[0106] Figure 5 shows the binding activity of humanized nanobody HuNb7 to cynomolgus monkey IL-18R1 stably transfected cell line (FACS).
[0107] Figure 6 shows the binding activity of humanized Nanobody HuNb24 to human IL-18R1 stably transfected cell lines (FACS).
[0108] Figure 7 shows the binding activity of humanized nanobody HuNb24 to cynomolgus monkey IL-18R1 stably transfected cell line (FACS). DETAILED DESCRIPTION
[0109] After extensive and in-depth research and extensive screening, the inventors unexpectedly discovered a class of IL-18R1 nanobodies for the first time. Experimental results show that the IL-18R1 nanobodies of the present invention can specifically recognize IL-18R1 in humans and cynomolgus monkeys, with good specificity and binding activity. In addition, the nanobodies of the present invention have good IL-18 / IL-18R pathway blocking activity, and the blocking activity is better than that of interleukin-18 binding protein (IL-18BP). Therefore, they can be used to prepare effective antibody drugs for treating diseases related to the IL-18 / IL-18R pathway. On this basis, the present invention was completed.
[0110] the term
[0111] As used herein, the terms "Nanoantibodies of the present invention", "anti-IL-18R1 Nanoantibodies of the present invention", "IL-18R1 Nanoantibodies of the present invention", "anti-IL-18R1 Nanoantibodies", and "IL-18R1 Nanoantibodies" have the same meaning and are used interchangeably, all referring to Nanoantibodies that specifically recognize and bind to IL-18R1 (including human IL-18R1 and cynomolgus monkey IL-18R1).
[0112] As used herein, the terms "antibody" or "immunoglobulin" are heterotetrameric glycoproteins of approximately 150,000 daltons with identical structural features, consisting of two identical light chains (L) and two identical heavy chains (H). Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide bonds varies between heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. Each heavy chain has a variable region (VH) at one end, followed by multiple constant regions. Each light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of the light chain is opposite the first constant region of the heavy chain, and the variable region of the light chain is opposite the variable region of the heavy chain. Specific amino acid residues form an interface between the variable regions of the light and heavy chains.
[0113] As used herein, the terms "single-domain antibody," "nanobody," and "single-domain antibody (sdAb)" have the same meaning and are used interchangeably. They refer to the cloning of the variable region of an antibody heavy chain to construct a nanobody consisting solely of a single heavy chain variable region, which is the smallest fully functional antigen-binding fragment, the VHH chain. Typically, an antibody naturally lacking the light chain and heavy chain constant region 1 (CH1) is first obtained, and then the variable region of the antibody heavy chain is cloned to construct a nanobody consisting solely of a single heavy chain variable region.
[0114] As used herein, the term "variable" refers to certain portions of the variable region in an antibody that differ in sequence, forming the binding and specificity of various specific antibodies to their specific antigens. However, variability is not evenly distributed throughout the entire antibody variable region. It is concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions in the light and heavy chain variable regions. The more conserved portions of the variable region are called framework regions (FRs). The variable regions of native heavy and light chains each contain four FR regions, which are generally in a β-folded configuration, connected by three CDRs that form a connecting loop, and in some cases can form a partial β-folded structure. The CDRs in each chain are closely together through the FR region and, together with the CDRs of the other chain, form the antigen-binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Volume 1, pages 647-669 (1991)). The constant regions do not directly participate in the binding of the antibody to the antigen, but they exhibit different effector functions, such as participating in the antibody's antibody-dependent cytotoxicity.
[0115] As known to those skilled in the art, immunoconjugates and fusion expression products include conjugates formed by binding drugs, toxins, cytokines, radionuclides, enzymes, and other diagnostic or therapeutic molecules to the antibodies or fragments thereof of the present invention. The present invention also includes cell surface markers or antigens bound to the anti-IL-18R1 antibodies or fragments thereof.
[0116] As used herein, the terms "heavy chain variable region" and "VH" are used interchangeably.
[0117] As used herein, the terms "variable region" and "complementarity determining region (CDR)" are used interchangeably.
[0118] In a preferred embodiment of the present invention, the heavy chain variable region of the antibody includes three complementarity determining regions CDR1, CDR2, and CDR3.
[0119] In a preferred embodiment of the present invention, the heavy chain of the antibody includes the above-mentioned heavy chain variable region and heavy chain constant region.
[0120] In the present invention, the terms "antibody of the present invention," "protein of the present invention," or "polypeptide of the present invention" are used interchangeably to refer to polypeptides that specifically bind to the IL-18R1 protein, such as proteins or polypeptides having a heavy chain variable region. These may or may not contain an initial methionine.
[0121] The present invention also provides other proteins or fusion expression products comprising the antibodies of the present invention. Specifically, the present invention includes any protein or protein conjugate and fusion expression product (i.e., immunoconjugate and fusion expression product) comprising a heavy chain containing a variable region, as long as the variable region is identical to or at least 90% homologous to the heavy chain variable region of the antibodies of the present invention, preferably at least 95% homologous.
[0122] Generally, an antibody's antigen-binding properties are described by three specific regions within the variable region of the heavy chain, known as the variable regions (CDRs). This region is divided into four framework regions (FRs). The amino acid sequences of the four FRs are relatively conserved and do not directly participate in the binding reaction. These CDRs form a loop structure, spatially close to each other through the β-sheet formed by the FRs between them. The CDRs on the heavy chain and the corresponding CDRs on the light chain constitute the antibody's antigen-binding site. The amino acid sequences of antibodies of the same type can be compared to determine which amino acids constitute the FR or CDR regions.
[0123] The variable regions of the heavy chains of the antibodies of the present invention are of particular interest because they are at least partially involved in antigen binding. Thus, the present invention includes molecules having antibody heavy chain variable regions with CDRs that are 90% or more (preferably 95% or more, and most preferably 98% or more) homologous to the CDRs identified herein.
[0124] The present invention includes not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Therefore, the present invention also includes fragments, derivatives and analogs of the antibodies.
[0125] As used herein, the terms "fragment," "derivative," and "analog" refer to polypeptides that substantially retain the same biological function or activity as the antibodies of the present invention. A polypeptide fragment, derivative, or analog of the present invention may be (i) a polypeptide having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, where such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a polypeptide formed by fusion of a mature polypeptide with another compound (e.g., a compound that extends the half-life of the polypeptide, such as polyethylene glycol), or (iv) a polypeptide formed by fusion of an additional amino acid sequence to the polypeptide sequence (e.g., a leader sequence or secretory sequence, or a sequence or proprotein sequence used to purify the polypeptide, or a fusion protein formed with a 6His tag). Based on the teachings herein, these fragments, derivatives, and analogs are well known to those skilled in the art.
[0126] The antibodies of the present invention refer to polypeptides that have IL-18R1 binding activity and include the aforementioned CDR regions. The term also encompasses variants of polypeptides that include the aforementioned CDR regions and have the same function as the antibodies of the present invention. These variants include (but are not limited to): deletions, insertions, and / or substitutions of one or more (generally 1-50, preferably 1-30, more preferably 1-20, and most preferably 1-10) amino acids, as well as the addition of one or more (generally within 20, preferably within 10, and more preferably within 5) amino acids to the C-terminus and / or N-terminus. For example, substitutions with amino acids having similar or similar properties generally do not alter protein function. For another example, the addition of one or more amino acids to the C-terminus and / or N-terminus generally does not alter protein function. The term also encompasses active fragments and active derivatives of the antibodies of the present invention.
[0127] Variant forms of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that can hybridize with the encoding DNA of the antibody of the present invention under high or low stringency conditions, and polypeptides or proteins obtained using antiserum against the antibody of the present invention.
[0128] The invention also provides other polypeptides, such as fusion proteins comprising Nanobodies or fragments thereof. In addition to nearly full-length polypeptides, the invention also encompasses fragments of the Nanobodies of the invention. Typically, the fragment will have at least about 50 consecutive amino acids of an antibody of the invention, preferably at least about 50 consecutive amino acids, more preferably at least about 80 consecutive amino acids, and most preferably at least about 100 consecutive amino acids.
[0129] In the present invention, "conservative variants of the antibodies of the present invention" refer to polypeptides in which no more than 10, preferably no more than 8, more preferably no more than 5, and most preferably no more than 3 amino acids are replaced with amino acids having similar or similar properties, compared to the amino acid sequence of the antibodies of the present invention. These conservative variant polypeptides are preferably generated by making amino acid substitutions according to Table A.
[0130] Table A
[0131] The present invention also provides polynucleotide molecules encoding the above-mentioned antibodies, fragments thereof, or fusion proteins thereof. The polynucleotides of the present invention may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA, or synthetic DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand.
[0132] The polynucleotide encoding the mature polypeptide of the present invention includes: a coding sequence encoding only the mature polypeptide; a coding sequence of the mature polypeptide and various additional coding sequences; a coding sequence of the mature polypeptide (and optional additional coding sequences) and non-coding sequences.
[0133] The term "polynucleotide encoding a polypeptide" may include a polynucleotide encoding the polypeptide, or may also include additional coding and / or non-coding sequences.
[0134] The present invention also relates to polynucleotides that hybridize to the above-mentioned sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that hybridize to the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) the addition of a denaturing agent during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, preferably at least 95%. Furthermore, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
[0135] The full-length nucleotide sequence of the antibody of the present invention or its fragments can generally be obtained by PCR amplification, recombinant methods, or artificial synthesis methods. One feasible method is to synthesize the relevant sequence by artificial synthesis, especially when the fragment length is relatively short. Generally, by first synthesizing multiple small fragments and then ligating them, very long fragments of sequence can be obtained. In addition, the coding sequence of the heavy chain can be fused with an expression tag (such as 6His) to form a fusion protein.
[0136] Once the relevant sequence is obtained, recombinant methods can be used to obtain it in large quantities. This is typically accomplished by cloning it into a vector, transferring it into cells, and then isolating the relevant sequence from the proliferated host cells using conventional methods. The biomolecules (nucleic acids, proteins, etc.) referred to in the present invention include biomolecules in isolated form.
[0137] Currently, DNA sequences encoding proteins of the present invention (or fragments thereof, or derivatives thereof) can be obtained entirely by chemical synthesis. This DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into protein sequences of the present invention by chemical synthesis.
[0138] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins.
[0139] Host cells can be prokaryotic cells, such as bacterial cells; lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2 or Sf9; and animal cells such as CHO, COS7, and 293 cells.
[0140] Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated using the CaCl2 method, using procedures well known in the art. Another method is to use MgCl2. If desired, transformation can also be performed using electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0141] The obtained transformants can be cultured using conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced using a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0142] The recombinant polypeptide in the above method can be expressed intracellularly, on the cell membrane, or secreted extracellularly. If necessary, the recombinant protein can be isolated and purified by various separation methods utilizing its physical, chemical, and other properties. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to, conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultrafiltration, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC), and various other liquid chromatography techniques and combinations of these methods.
[0143] The antibodies of the present invention may be used alone or in combination with a detectable label (for diagnostic purposes), a therapeutic agent, a PK (protein kinase) modifying moiety, or any combination of these.
[0144] Detectable labels for diagnostic purposes include, but are not limited to, fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or enzymes capable of producing a detectable product.
[0145] Therapeutic agents that can be combined or coupled with the antibodies of the present invention include but are not limited to: 1. radionuclides; 2. biological toxins; 3. cytokines such as IL-2; 4. gold nanoparticles / nanorods; 5. viral particles; 6. liposomes; 7. nanomagnetic particles; 8. prodrug activating enzymes (for example, DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)), etc.
[0146] IL-18R1 Nanobody of the Present Invention
[0147] In the present invention, the amino acid sequence of the VHH chain of the anti-IL-18R1 nanobody is selected from one or more of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4.
[0148] Nb7 amino acid sequence (SEQ ID NO: 1)
[0149] QVQLQESGGGSVHAGETLRLSCTYSGFTFDDSDMDWYRQAPGNECELVAVIDSDGSTYYADSVKGRFAISIDNAKNTVYLQMNSLKPEDTAVYYCAAEWGPAHGDYGCVGQGTQVTVSS (the underlined parts are CDR1, CDR2 and CDR3, respectively)
[0150] Nb24 amino acid sequence (SEQ ID NO: 2)
[0151] QVQLQESGGGSVQAGETLRLSCTASRFSFDDFDMGWFRQAPGNECELVSTISSDGSTYYADSVKGRFTISQDNAKKTVFLQMNSLKPEDTAVYYCAAEWTGNWDELQCWGQGTQVTVSS (the underlined parts are CDR1, CDR2 and CDR3, respectively)
[0152] HuNb7 amino acid sequence (SEQ ID NO: 3)
[0153] EVQLLESGGGLVHPGETLRLSCTYSGFTFDDSDMDWYRQAPGNECELVAVIDSDGSTYYADSVKGRFAISIDNAKNTVYLQMNSLKPEDTAVYYCAAEWGPAHGDYGCVGQGTLVTVSS (the underlined parts are CDR1, CDR2 and CDR3, respectively)
[0154] HuNb24 amino acid sequence (SEQ ID NO: 4)
[0155] EVQLLESGGGLVQPGETLRLSCTASRFSFDDFDMGWFRQAPGNECELVSTISSDGSTYYADSVKGRFTISQDNAKKTVFLQMNSLKPEDTAVYYCAAEWTGNWDELQCWGQGTLVTVSS (the underlined parts are CDR1, CDR2 and CDR3, respectively)
[0156] An exemplary nucleotide sequence encoding the VHH chain of the above-mentioned IL-18R1 Nanobody is as follows:
[0157] Nb7 nucleotide sequence (SEQ ID NO: 5)
[0158] Nb24 nucleotide sequence (SEQ ID NO: 6)
[0159] HuNb7 nucleotide sequence (SEQ ID NO: 7)
[0160] HuNb24 nucleotide sequence (SEQ ID NO: 8)
[0161] Pharmaceutical composition
[0162] The present invention also provides a composition. Preferably, the composition is a pharmaceutical composition comprising the above-mentioned antibody, active fragment thereof, or fusion protein thereof, and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH value may vary depending on the nature of the formulated substance and the condition to be treated. The formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to): intraperitoneal, intravenous, or topical administration.
[0163] The pharmaceutical composition of the present invention can be used to directly bind to the IL-18R1 protein molecule, blocking the IL-18 / IL-18R pathway. Therefore, it can be used to treat diseases related to the IL-18 / IL-18R pathway, including autoimmune or inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus, type 1 diabetes, atopic dermatitis, psoriasis, inflammatory bowel disease, and rare diseases such as hemophagocytic lymphohistiocytosis (HLH) and adult-onset Still's disease. In addition, other therapeutic agents can be used simultaneously.
[0164] The pharmaceutical composition of the present invention contains a safe and effective amount (such as 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80wt%) of the above-mentioned nanoantibody (or its conjugate) of the present invention and a pharmaceutically acceptable carrier or excipient. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, using physiological saline or an aqueous solution containing glucose and other adjuvants by conventional methods. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 10 micrograms / kg body weight to about 50 mg / kg body weight per day. In addition, the polypeptide of the present invention can also be used with other therapeutic agents.
[0165] When using a pharmaceutical composition, a safe and effective amount of the immunoconjugate is administered to a mammal, wherein the safe and effective amount is generally at least about 10 μg / kg body weight, and in most cases does not exceed about 50 mg / kg body weight. Preferably, the dose is about 10 μg / kg body weight to about 10 mg / kg body weight. Of course, the specific dose should also take into account factors such as the route of administration and the patient's health status, which are all within the skill of a skilled physician.
[0166] Labeled nanobodies
[0167] In one embodiment of the present invention, the Nanobody carries a detectable label. More preferably, the label is selected from the group consisting of an isotope, a colloidal gold label, a colored label, or a fluorescent label.
[0168] Colloidal gold labeling can be performed using methods known to those skilled in the art. In a preferred embodiment of the present invention, the nanobody against IL-18R1 is labeled with colloidal gold to obtain a colloidal gold-labeled nanobody.
[0169] Detection method
[0170] The present invention also relates to a method for detecting IL-18R1 protein. The method generally comprises the following steps: obtaining a cell and / or tissue sample; dissolving the sample in a medium; and detecting the level of IL-18R1 protein in the dissolved sample.
[0171] In the detection method of the present invention, the sample used is not particularly limited, and a representative example is a sample containing cells in a cell storage medium.
[0172] Reagent test kit
[0173] The present invention also provides a kit containing the antibody (or fragment thereof) or detection plate of the present invention. In a preferred embodiment of the present invention, the kit further includes a container, instructions for use, a buffer, etc.
[0174] The present invention also provides a detection kit for detecting IL-18R1 levels, which includes an antibody that recognizes the IL-18R1 protein, a lysis medium for dissolving the sample, and common reagents and buffers required for detection, such as various buffers, detection labels, and detection substrates. The detection kit can be an in vitro diagnostic device.
[0175] application
[0176] As described above, the Nanobodies of the present invention have broad biological and clinical applications, encompassing a wide range of fields, including the diagnosis and treatment of diseases related to the IL-18 / IL-18R pathway, basic medical research, and biological research. A preferred application is in the clinical diagnosis and targeted therapy of IL-18R1.
[0177] The following specific examples further illustrate the present invention. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally carried out under conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight. The materials, reagents, instruments, etc. used in the examples, unless otherwise specified, can be obtained from commercial sources.
[0178] Example 1: Screening and identification of IL-18R1 nanobodies
[0179] The IL-18R1 extracellular segment gene (Uniprot: Q13478AA22-329) was cloned and synthesized into the pFUSE vector according to the human codon-optimized base sequence. The vector was then transfected into HEK293F cells and the human IL-18R1ECD-Fc fusion protein was purified by protein A affinity chromatography. The highly purified protein was mixed with an immune adjuvant and immunized into two Xinjiang Bactrian camels once a week. After seven immunizations, peripheral blood was collected from the camels, RNA was isolated, and the VHH gene fragment was transcribed and amplified. It was then cloned into the pMECS vector and electroporated into TG1 competent cells to establish a high-quality phage display nanoantibody library. After testing, the library capacity of both libraries reached 1×10 9 CFU and above, and the fragment insertion rate was above 90%.
[0180] Phage display technology was then used to screen for IL-18R1-specific Nanobodies (see Example 2 of patent CN110144009B for the screening method). After four rounds of "adsorption-wash-enrichment" (adsorption-washing-enrichment), both libraries showed a 15-fold or greater enrichment of specific Nanobodies. Six hundred clones were randomly selected for ELISA testing, and all positive clones were sequenced and analyzed to express antibodies from all different families (with CDR3 differences).
[0181] Example 2: Construction and expression of humanized IL-18R1 nanobody
[0182] After humanization (for humanization methods, see Example 4 in patent CN2018101517526), antibody sequences from different families were synthesized into the pPICZaA vector using a Pichia pastoris codon-optimized base sequence. The recombinant plasmid containing the antibody gene was linearized and electroporated into Pichia pastoris X33 competent cells. Single clones were then isolated from resistant plates and induced for expression with methanol. The antibody expression levels in the culture medium were then measured. The results of the humanized IL-18R1 nanobody expression assay are shown in Table 1.
[0183] Table 1 Statistical results of expression of humanized IL-18R1 nanobody in Pichia pastoris
[0184] Example 3: Detection of the inhibitory effect of IL-18R1 nanobody on cell signaling pathways
[0185] HEK293IL-18R reporter cells were used to test the blocking effect of candidate antibodies on IL-18 and cell-expressed IL-18R. The number of HEK293IL-18R reporter cells required for each sample was adjusted to 1×10 4 IL-18 at a working concentration of 40 ng / mL, or a gradient dilution of the candidate antibody or IL-18BP (4-fold gradient, 10 points) were added to each well and incubated at 37°C for 24 hours. Luciferase reporter gene detection substrate was then added, and the cells were incubated in the dark for 5 minutes before fluorescence intensity was measured on a microscope.
[0186] The results showed that the candidate antibodies had good blocking activity on the IL-18-activated HEK293IL-18R reporter gene cell signaling pathway, as shown in Figure 1, among which HuNb7 and HuNb24 were better IL-18 / IL-18R pathway inhibitors.
[0187] The sequences of HuNb7 and HuNb24 and their camel-derived nanobodies Nb7 and Nb24 before humanization are shown in Table 2 below:
[0188] Table 2
[0189] Example 4: ELISA detection of the binding activity of IL-18R1 nanobody
[0190] The binding activity of candidate nanobodies was tested using ELISA. A 96-well microtiter plate was coated with human IL-18R1 extracellular domain protein and incubated at 37°C for 2 hours. After washing with PBST, the plate was blocked with BSA blocking buffer at 37°C for 2 hours. After washing with PBST, serially diluted nanobodies were added and incubated at 37°C for 1 hour. After washing with PBST, diluted biotinylated anti-his antibody was added, followed by diluted SA-HRP. After washing with PBST, the plate was added with color development buffer and stop buffer, and the absorbance was measured with a microtiter plate reader.
[0191] The results are shown in Figures 2 and 3 , showing that both humanized antibodies HuNb7 and HuNb24 can effectively bind to human and cynomolgus monkey IL-18R1.
[0192] Example 5: FACS detection of IL-18R1 nanobody binding activity
[0193] Flow cytometry was used to assess the binding activity of candidate antibodies to human and cynomolgus macaque IL-18R1 on cell surfaces. 293T-hIL-18R1, a stably transfected cell line overexpressing human IL-18R1, and 293T-CynoIL-18R1, a stably transfected cell line overexpressing cynomolgus macaque IL-18R1, were aliquoted into 96-well plates, with 3E5 cells per well. Serially diluted antibodies were added and incubated at room temperature for 30 minutes. The cells were washed twice with PBS and incubated with diluted anti-HA antibody-APC for 30 minutes at room temperature. The cells were washed again with PBS before analysis.
[0194] The results showed that, as shown in Figures 4-7, candidate antibodies HuNb7 and HuNb24 both had good binding activity to cell surface human IL-18R1 and cynomolgus monkey IL-18R1.
[0195] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. An anti-IL-18R1 nanobody, characterized in that The Nanobody is capable of specifically binding to IL-18R1, and the complementarity determining region (CDR) of the VHH chain in the Nanobody is one or more selected from the following groups: (1) CDR1 shown in SEQ ID NO: 12, CDR2 shown in SEQ ID NO: 13, and CDR3 shown in SEQ ID NO: 14, and (2) CDR1 shown in SEQ ID NO:9, CDR2 shown in SEQ ID NO:10, and CDR3 shown in SEQ ID NO:
11.
2. An anti-IL-18R1 antibody, characterized in that: The antibody comprises the VHH chain of the anti-IL-18R1 nanobody according to claim 1.
3. An anti-IL-18R1 nanobody Fc fusion protein, the structure of the fusion protein from N-terminus to C-terminus is as shown in Formula Ia or Ib: ALB (Ia); BLA (Ib); in, "-" is a peptide bond; A is one or more anti-IL-18R1 Nanobodies as claimed in claim 1; B is the Fc fragment of IgG; and L is no or flexible joint.
4. A polynucleotide, characterized in that The polynucleotide encodes a protein selected from the group consisting of the anti-IL-18R1 nanobody according to claim 1, the anti-IL-18R1 antibody according to claim 2, or the anti-IL-18R1 nanobody Fc fusion protein according to claim 3.
5. An expression vector, characterized in that: The expression vector contains the polynucleotide according to claim 4.
6. A host cell, comprising the expression vector according to claim 5, or the polynucleotide according to claim 4 is integrated into its genome.
7. An immunoconjugate, characterized in that: The immunoconjugate comprises: (a) the anti-IL-18R1 Nanobody according to claim 1, or the anti-IL-18R1 antibody according to claim 2, or the anti-IL-18R1 Nanobody Fc fusion protein according to claim 3; and (b) a conjugated moiety selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, a gold nanoparticle / nanorod, a nanomagnetic particle, a viral coat protein or a VLP, or a combination thereof.
8. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises: (i) the anti-IL-18R1 nanobody according to claim 1, or the anti-IL-18R1 antibody according to claim 2, or the anti-IL-18R1 nanobody Fc fusion protein according to claim 3, or the immunoconjugate according to claim 7; and (ii) a pharmaceutically acceptable carrier.
9. Use of the anti-IL-18R1 nanobody according to claim 1, or the anti-IL-18R1 antibody according to claim 2, or the anti-IL-18R1 nanobody Fc fusion protein according to claim 3, or the immunoconjugate according to claim 7 for: (a) preparing a drug for preventing and / or treating a disease or condition related to the IL-18 / IL-18R pathway; (b) preparing a reagent, a detection plate or a kit for detecting IL-18R1. 10 . A multispecific antibody comprising the anti-IL-18R1 nanobody according to claim 1 , or the anti-IL-18R1 antibody according to claim 2 .
11. Use of the anti-IL-18R1 nanobody according to claim 1, or the anti-IL-18R1 antibody according to claim 2, or the anti-IL-18R1 nanobody Fc fusion protein according to claim 3, or the immunoconjugate according to claim 7 for detecting IL-18R1 protein in a sample, or for treating and / or preventing diseases or disorders related to the IL-18 / IL-18R pathway.
12. A recombinant protein, comprising: (Z1) the anti-IL-18R1 nanobody according to claim 1, or the anti-IL-18R1 antibody according to claim 2, or the anti-IL-18R1 nanobody Fc fusion protein according to claim 3; and (Z2) Optional tag sequence to facilitate expression and / or purification.
13. A IL-18R1 protein detection reagent, comprising: (C1) the anti-IL-18R1 nanobody according to claim 1, or the anti-IL-18R1 antibody according to claim 2, or the anti-IL-18R1 nanobody Fc fusion protein according to claim 3, or the immunoconjugate according to claim 7; and (C2) A carrier that is acceptable for detection.
14. An IL-18 inhibitor, comprising the anti-IL-18R1 nanobody according to claim 1, or the anti-IL-18R1 antibody according to claim 2, or the anti-IL-18R1 nanobody Fc fusion protein according to claim 3.
15. A chimeric antigen receptor, characterized in that The antigen binding domain of the chimeric antigen receptor comprises the anti-IL-18R1 nanobody according to claim 1 or the anti-IL-18R1 antibody according to claim 2.
Citation Information
Patent Citations
Antibodies that bind human interleukin-18 and methods of making and using
CN102206277A
IL-18 binding proteins
CN102659944A
Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
CN1780911A
Antibodies against il-18r1 and uses thereof
WO2012025536A1
AU2004235595A1
Cited By
IL-18 nano antibody, antibody pair and preparation method and application thereof
CN120349413A
